ClinicalTrials.gg
RecruitingNCT06517355ABSENSUpdated Nov 10, 2026

Acceptability and Benefits of an Onco-sexology Program for Laryngectomy Patients and Their Partners

An observational study in ORL Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Institut Claudius Regaud · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

Single-centre prospective pilot study designed to demonstrate the acceptability of onco-sexology management for laryngectomy patients and their partners in order to improve their perception of their intimate life. This is a non-interventional study (category 3 Loi Jardé), which will not result in any change in patient management. All procedures will be carried out in accordance with standard practice.

Patients will be followed for 14 months.

02

Conditions studied

  • ORL Cancer

Keywords

  • ORL cancer
  • Onco-sexology care
  • Laryngectomy
03

In context

Lead sponsor

Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with cancer (ORL) treated by laryngectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients:

  1. Patient to be treated for ORL cancer by total (pharyngo)laryngectomy
  2. Patient WHO 0-1-2
  3. Age greater than or equal to 18 years
  4. Patient who has not objected to participation in the study.

For partners (if applicable) :

  1. Age greater than or equal to 18 years
  2. Subject who has not objected to participation in the study.

Exclusion criteria

Exclusion Criteria:

For patients:

  1. Patient with another co-existing malignant disease at the time of inclusion.
  2. Any psychological, familial, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures foreseen in the study protocol.
  3. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).

For partners (if applicable):

1. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with cancer (ORL) treated by laryngectomy

    Other: In this research, the procedure under study is represented:

Interventions

  • OtherIn this research, the procedure under study is represented:

    * On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse. * Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation.

06

What researchers measure

Primary outcomes

  1. The primary endpoint is defined as the rate of patients meeting the acceptability criteria for onco-sexology management.

    This rate corresponds to the ratio of the number of patients meeting the acceptability criteria to the total number of patients included. Acceptability is defined when the following two criteria are validated: * Completion of onco-sexology consultations 2 and 3 (at 3 and 12 months after cancer treatment) * Patient satisfaction ≥ 3 on a numerical scale from 1 to 5.

    Time frame: 14 months for each patient

Secondary outcomes

  1. For the patients: Patients' sexual satisfaction will be assessed using the specific scale of the EORTC QLQSHQ-C22 questionnaire.

    The score, which ranges from 0 to 100, is determined according to the algorithm published by the EORTC, based on answers to 8 questions. This is a self-administered questionnaire validated in French

    Time frame: 14 months for each patient

  2. For the patients: Quality of life will be assessed using the EORTC QLQ-C30 questionnaire and the disease-specific QLQ-H&N43 questionnaire.

    These are self-administered questionnaires validated in French.

    Time frame: 14 months for each patient

  3. For the patients: The female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm).

    The FSFI (Female Sexual Function Index) is a self-administered questionnaire validated in French. It comprises 19 items studying 6 dimensions of female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm) which make up an overall score of between 2 and 36.

    Time frame: 14 months for each patient

  4. For the patients: The ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).

    The MSHQ (Male Sexual Health Questionnaire) is a self-questionnaire validated in French which assesses the ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).

    Time frame: 14 months for each patient

  5. For the patients: The impact of (pharyngo)laryngectomy totale on the couple's relationship.

    It will be assessed using a descriptive analysis (marital status before and after cancer treatment, stability, strengthening or deterioration of the couple's relationship).

    Time frame: 14 months for each patient

  6. For the patients: Satisfaction or dissatisfaction with the onco-sexology consultation.

    It will be assessed using a Likert scale. This type of scale was developed to measure attitudes and opinions (Rensis Likert 'A Technique for the Measurement of Attitudes', Archives of Psychology, vol.140, 1932, p. 1-55).

    Time frame: 14 months for each patient

  7. For the partner: - The rate of partners verifying the acceptability criteria for onco-sexology management is defined by the ratio of the number of partners verifying the acceptability criteria to the total number of partners included.

    The definition of acceptability is the same as for the primary endpoint.

    Time frame: 14 months for each partner

  8. For the partner: The impact of the (pharyngo)laryngectomy totale on the couple's relationship will be assessed using a descriptive analysis (stability, reinforcement or deterioration of the couple's life).

    Time frame: 14 months for each partner

  9. For the partner: Satisfaction or dissatisfaction with the onco-sexology consultation will be assessed using a Likert scale.

    Time frame: 14 months for each partner

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2024 (actual). Primary completion is estimated for Sep 2030, 74 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Mar 2028 → Sep 2030 and completion Mar 2028 → Sep 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 24, 2024
StartActual
Jul 30, 2024
Primary completionEst.
Sep 30, 2030was Mar 2028
CompletionEst.
Sep 30, 2030was Mar 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2028→Sep 30, 2030
Nov 10, 2026
Study completion
Mar 2028→Sep 30, 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Mar 2028→Sep 30, 2030
    Study completion Mar 2028→Sep 30, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06517355
Responsible party
Sponsor
First posted
Jul 24, 2024
Start date
Jul 30, 2024
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Julienne VIDAL
Contact
vidal.julienne@iuct-oncopole.fr
05 31 15 51 36

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion